OBJECTIVES: HIV virological failure remains a major threat to programme success in sub-Saharan Africa. While HIV drug resistance (HIVDR) and inadequate adherence are the main drivers of virological failure, the individual, clinical and health system characteristics that lead to poor outcomes are not well understood. The objective of this paper is to identify those characteristics among people failing first-line antiretroviral therapy (ART). METHODS: We enrolled a cohort of adults in HIV care experiencing virological failure on first-line ART at five sites and used standard statistical methods to characterize them with a focus on three domains: individual/demographic, clinical, and health system, and compared each by country of enrolment. RESULTS: Of 840 participants, 51% were women, the median duration on ART was 3.2 years [interquartile range (IQR) 1.1, 6.4 years] and the median CD4 cell count prior to failure was 281 cells/µL (IQR 121, 457 cells/µL). More than half of participants [53%; 95% confidence interval (CI) 49-56%] stated that they had > 90% adherence and 75% (95% CI 72-77%) took their ART on time all or most of the time. Conversely, the vast majority (90%; 95% CI 86-92%) with a completed genotypic drug resistance test had any HIV drug resistance. This population had high health system use, reporting a median of 3 (IQR 2.6) health care visits and a median of 1 (IQR 1.1) hospitalization in the preceding 6 months. CONCLUSIONS: Patients failing first-line ART in sub-Saharan Africa generally report high rates of adherence to ART, have extremely high rates of HIV drug resistance and utilize significant health care resources. Health systems interventions to promptly detect and manage treatment failure will be a prerequisite to establishing control of the HIV epidemic.
OBJECTIVES: HIV virological failure remains a major threat to programme success in sub-Saharan Africa. While HIV drug resistance (HIVDR) and inadequate adherence are the main drivers of virological failure, the individual, clinical and health system characteristics that lead to poor outcomes are not well understood. The objective of this paper is to identify those characteristics among people failing first-line antiretroviral therapy (ART). METHODS: We enrolled a cohort of adults in HIV care experiencing virological failure on first-line ART at five sites and used standard statistical methods to characterize them with a focus on three domains: individual/demographic, clinical, and health system, and compared each by country of enrolment. RESULTS: Of 840 participants, 51% were women, the median duration on ART was 3.2 years [interquartile range (IQR) 1.1, 6.4 years] and the median CD4 cell count prior to failure was 281 cells/µL (IQR 121, 457 cells/µL). More than half of participants [53%; 95% confidence interval (CI) 49-56%] stated that they had > 90% adherence and 75% (95% CI 72-77%) took their ART on time all or most of the time. Conversely, the vast majority (90%; 95% CI 86-92%) with a completed genotypic drug resistance test had any HIV drug resistance. This population had high health system use, reporting a median of 3 (IQR 2.6) health care visits and a median of 1 (IQR 1.1) hospitalization in the preceding 6 months. CONCLUSIONS: Patients failing first-line ART in sub-Saharan Africa generally report high rates of adherence to ART, have extremely high rates of HIV drug resistance and utilize significant health care resources. Health systems interventions to promptly detect and manage treatment failure will be a prerequisite to establishing control of the HIV epidemic.
Authors: A Cozzi-Lepri; A N Phillips; B Clotet; J Kjaer; V Von Wyl; G Kronborg; A Castagna; J R Bogner; J D Lundgren Journal: HIV Med Date: 2011-08-17 Impact factor: 3.180
Authors: Nicholas Musinguzi; Collins D Muganzi; Yap Boum; Allan Ronald; Mark A Marzinke; Craig W Hendrix; Connie Celum; Jared M Baeten; David R Bangsberg; Jessica E Haberer Journal: AIDS Date: 2016-04-24 Impact factor: 4.177
Authors: Andreas D Haas; Olivia Keiser; Eric Balestre; Steve Brown; Emmanuel Bissagnene; Cleophas Chimbetete; François Dabis; Mary-Ann Davies; Christopher J Hoffmann; Patrick Oyaro; Rosalind Parkes-Ratanshi; Steven J Reynolds; Izukanji Sikazwe; Kara Wools-Kaloustian; D Marcel Zannou; Gilles Wandeler; Matthias Egger Journal: Lancet HIV Date: 2015-06-16 Impact factor: 12.767
Authors: Mark J Siedner; Mwebesa B Bwana; Mahomed-Yunus S Moosa; Michelle Paul; Selvan Pillay; Suzanne McCluskey; Isaac Aturinda; Kevin Ard; Winnie Muyindike; Pravikrishnen Moodley; Jaysingh Brijkumar; Tamlyn Rautenberg; Gavin George; Brent Johnson; Rajesh T Gandhi; Henry Sunpath; Vincent C Marconi Journal: HIV Clin Trials Date: 2017-07-18
Authors: Niklaus Daniel Labhardt; Isaac Ringera; Thabo Ishmael Lejone; Molisana Cheleboi; Sarah Wagner; Josephine Muhairwe; Thomas Klimkait Journal: J Int AIDS Soc Date: 2017-07-19 Impact factor: 5.396
Authors: Francis Kiweewa; Allahna Esber; Ezra Musingye; Domonique Reed; Trevor A Crowell; Fatim Cham; Michael Semwogerere; Rosemary Namagembe; Alice Nambuya; Cate Kafeero; Allan Tindikahwa; Leigh Anne Eller; Monica Millard; Huub C Gelderblom; Babajide Keshinro; Yakubu Adamu; Jonah Maswai; John Owuoth; Valentine Chepkorir Sing'oei; Lucas Maganga; Emmanuel Bahemana; Samoel Khamadi; Merlin L Robb; Julie A Ake; Christina S Polyak; Hannah Kibuuka Journal: PLoS One Date: 2019-02-05 Impact factor: 3.240
Authors: Sophie Js Pascoe; Matthew P Fox; Amy N Huber; Joshua Murphy; Mokgadi Phokojoe; Marelize Gorgens; Sydney Rosen; David Wilson; Yogan Pillay; Nicole Fraser-Hurt Journal: J Int AIDS Soc Date: 2019-11 Impact factor: 5.396
Authors: Viktor von Wyl; Thomas Klimkait; Sabine Yerly; Dunja Nicca; Hansjakob Furrer; Matthias Cavassini; Alexandra Calmy; Enos Bernasconi; Jürg Böni; Vincent Aubert; Huldrych F Günthard; Heiner C Bucher; Tracy R Glass Journal: PLoS One Date: 2013-10-16 Impact factor: 3.240
Authors: Anna Grimsrud; Helen Bygrave; Meg Doherty; Peter Ehrenkranz; Tom Ellman; Robert Ferris; Nathan Ford; Bactrin Killingo; Lynette Mabote; Tara Mansell; Annette Reinisch; Isaac Zulu; Linda-Gail Bekker Journal: J Int AIDS Soc Date: 2016-12-01 Impact factor: 5.396